Retina (Philadelphia, Pa.) · 2026
COMPARISON OF PEDIATRIC PATIENTS WITH PARS PLANITIS WHO UNDERWENT TREATMENT VERSUS OBSERVATION AT A TERTIARY REFERRAL EYE CENTER.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xia Julia L, Shunyakova Jenny, Hwang Kate M, Milner Dallin C, Siddique Namoos, Patnaik Jennifer L, Hassman Lynn M, Reddy Amit K, Palestine Alan G, Jung Jennifer L
Аннотация
PURPOSE: To compare the characteristics of pediatric patients with pars planitis (PP) who received treatment versus those who were observed without treatment.
METHODS: Retrospective chart review of pediatric patients diagnosed with PP at a tertiary referral center from 2000 to 2024.
RESULTS: Of 158 eyes from 84 patients with PP, 127 eyes (80.4%) received treatment and 31 eyes (19.6%) were observed. Eyes that were observed presented with less anterior chamber cell ( P < 0.007), vitreous cell ( P = 0.0005), vitreous haze ( P = 0.003), and optic nerve head edema ( P = 0.03). The untreated group had significantly lower total fluorescein angiography scores ( P < 0.0001) than the treated group and specifically scored lower in disc leakage ( P = 0.006) and retinal capillary leakage ( P < 0.0001). In the treated group, 66 eyes (52%) developed ocular hypertension and 24 (18.9%) developed glaucoma, whereas the untreated group had no cases of either. Final visual acuity was similar between treated and untreated groups (20/32 vs. 20/25, P = 0.13), and no untreated eyes developed complications requiring surgery.
CONCLUSION: Not all patients with pediatric PP require treatment. Select mild cases may be safely observed without developing sequelae of chronic inflammation. Proper identification of these patients can reduce side effects and medication burden.
METHODS: Retrospective chart review of pediatric patients diagnosed with PP at a tertiary referral center from 2000 to 2024.
RESULTS: Of 158 eyes from 84 patients with PP, 127 eyes (80.4%) received treatment and 31 eyes (19.6%) were observed. Eyes that were observed presented with less anterior chamber cell ( P < 0.007), vitreous cell ( P = 0.0005), vitreous haze ( P = 0.003), and optic nerve head edema ( P = 0.03). The untreated group had significantly lower total fluorescein angiography scores ( P < 0.0001) than the treated group and specifically scored lower in disc leakage ( P = 0.006) and retinal capillary leakage ( P < 0.0001). In the treated group, 66 eyes (52%) developed ocular hypertension and 24 (18.9%) developed glaucoma, whereas the untreated group had no cases of either. Final visual acuity was similar between treated and untreated groups (20/32 vs. 20/25, P = 0.13), and no untreated eyes developed complications requiring surgery.
CONCLUSION: Not all patients with pediatric PP require treatment. Select mild cases may be safely observed without developing sequelae of chronic inflammation. Proper identification of these patients can reduce side effects and medication burden.